Nezam Afdhal

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?
    Nezam H Afdhal
    Hepatology 37:972-4. 2003
  2. ncbi request reprint Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts Electronic address
    Gastroenterology 146:442-52.e1. 2014
  3. ncbi request reprint Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia
    Nezam H Afdhal
    Division of Gastroenterology Liver Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 367:716-24. 2012
  4. doi request reprint Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    JAMA 308:608-16. 2012
  5. ncbi request reprint Can serum markers be used to reliably detect liver fibrosis?
    Nezam Afdhal
    Beth Israel Deaconess Medical Center and Harvard Medical School, MA 02215, USA
    Nat Clin Pract Gastroenterol Hepatol 2:132-3. 2005
  6. ncbi request reprint Introduction: thrombocytopenia in chronic liver disease -- treatment implications and novel approaches
    N H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Aliment Pharmacol Ther 26:1-4. 2007
  7. ncbi request reprint Role of epoetin alfa in maintaining ribavirin dose
    Nezam H Afdhal
    Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    Gastroenterol Clin North Am 33:S25-35. 2004
  8. ncbi request reprint Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection
    N H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Aliment Pharmacol Ther 26:29-39. 2007
  9. doi request reprint Thrombocytopenia associated with chronic liver disease
    Nezam Afdhal
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Hepatol 48:1000-7. 2008
  10. doi request reprint Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis
    Raza Malik
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Gastroenterol Hepatol 25:1562-8. 2010

Detail Information

Publications55

  1. ncbi request reprint Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?
    Nezam H Afdhal
    Hepatology 37:972-4. 2003
  2. ncbi request reprint Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts Electronic address
    Gastroenterology 146:442-52.e1. 2014
    ....
  3. ncbi request reprint Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia
    Nezam H Afdhal
    Division of Gastroenterology Liver Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 367:716-24. 2012
    ....
  4. doi request reprint Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    JAMA 308:608-16. 2012
    ..Improved noninvasive diagnostic tests, a clearer understanding of the natural history of NAFLD, and large, well-designed clinical trials are needed...
  5. ncbi request reprint Can serum markers be used to reliably detect liver fibrosis?
    Nezam Afdhal
    Beth Israel Deaconess Medical Center and Harvard Medical School, MA 02215, USA
    Nat Clin Pract Gastroenterol Hepatol 2:132-3. 2005
  6. ncbi request reprint Introduction: thrombocytopenia in chronic liver disease -- treatment implications and novel approaches
    N H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Aliment Pharmacol Ther 26:1-4. 2007
    ..Thrombocytopenia is a common hematologic toxicity among patients with chronic liver disease...
  7. ncbi request reprint Role of epoetin alfa in maintaining ribavirin dose
    Nezam H Afdhal
    Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    Gastroenterol Clin North Am 33:S25-35. 2004
    ....
  8. ncbi request reprint Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection
    N H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Aliment Pharmacol Ther 26:29-39. 2007
    ..Consequently, efforts have been directed toward developing novel approaches for the treatment of thrombocytopenia...
  9. doi request reprint Thrombocytopenia associated with chronic liver disease
    Nezam Afdhal
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Hepatol 48:1000-7. 2008
    ..The ability to increase platelet levels could significantly reduce the need for platelet transfusions and facilitate the use of interferon-based antiviral therapy and other medically indicated treatments in patients with liver disease...
  10. doi request reprint Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis
    Raza Malik
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Gastroenterol Hepatol 25:1562-8. 2010
    ..We therefore compared liver stiffness by transient elastography, APRI score, AST/ALT ratio, hyaluronic acid and clinical signs to determine which modality performed best at identifying compensated cirrhosis...
  11. ncbi request reprint The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease
    Raza Malik
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Suite 4A, Boston, Massachusetts, USA
    J Gastroenterol Hepatol 24:564-8. 2009
    ..We identified patients with nonalcoholic fatty liver disease (NAFLD) to determine the predictive value of serum markers to diagnose histological steatohepatitis (NASH)...
  12. ncbi request reprint Maintenance therapy for chronic hepatitis C
    T Barry Kelleher
    Department of Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 8E, Boston, MA 02115, USA
    Curr Gastroenterol Rep 7:50-3. 2005
    ....
  13. ncbi request reprint Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment
    Changqing Yang
    Department of Medicine and the Liver Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 63:8312-7. 2003
    ....
  14. ncbi request reprint Assessment of liver fibrosis in co-infected patients
    T Barry Kelleher
    Department of Hepatology, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    J Hepatol 44:S126-31. 2006
    ..Future trends for staging liver disease must not only focus on cross sectional diagnosis but on utilizing novel techniques to stratify risk for disease progression over time...
  15. pmc Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection
    Elliot B Tapper
    The Liver Center, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Gastroenterol Hepatol 10:932-937.e1. 2012
    ..Chronic inflammation from hepatitis C virus (HCV) infection is not considered to be one of these variables...
  16. ncbi request reprint Noninvasive assessment of liver fibrosis
    T Barry Kelleher
    Department of Hepatology, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    Clin Liver Dis 9:667-83, vii. 2005
    ..This article outlines the accuracy of all these modalities in the diagnosis of hepatic fibrosis and discusses how they may be incorporated into clinical practice...
  17. pmc Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C
    Norah A Terrault
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0538, USA
    Clin Gastroenterol Hepatol 6:1403-11. 2008
    ..Prior studies suggest the rate of liver fibrosis progression is slower in African Americans (AAs) than Caucasian Americans (CAs) with chronic HCV infection...
  18. ncbi request reprint Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells
    Emanuele Durante-Mangoni
    Infectious Diseases Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 173:2159-66. 2004
    ..This process may be beneficial in acute viral clearance, but in chronic infection could contribute to liver injury...
  19. ncbi request reprint Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV
    Camilla S Graham
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA
    Hepatology 40:125-32. 2004
    ..In conclusion, subjects with coinfection have an alteration of intrahepatic HCV-specific IL-10 cytokine response that may have implications for HCV-related disease progression...
  20. doi request reprint Evaluation of liver lesions
    Alan Bonder
    Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Clin Liver Dis 16:271-83. 2012
    ..Decisions regarding specific imaging modalities for diagnoses, the use of liver biopsy, therapeutic options, and appropriate follow-up are all determined by the presentation of the lesion and associated patient characteristics...
  21. doi request reprint Utilization of FibroScan in clinical practice
    Alan Bonder
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis street Suite 8E, Boston, MA, 02215, USA
    Curr Gastroenterol Rep 16:372. 2014
    ..In this review, we discuss the performance characteristics of elastography for a variety of liver diseases and highlight practical appropriate suggestions for how to incorporate this technology into clinical practice. ..
  22. pmc Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C
    Lucy Golden-Mason
    Division of Gastroenterology and Hepatology, Hepatitis C Center, Department of Medicine, University of Colorado Denver and National Jewish Hospital, Denver, CO, USA
    Hepatology 54:1559-69. 2011
    ....
  23. doi request reprint Liver masses and eosinophilia
    Michelle Lai
    Beth Israel Deaconess Medical Center, Division of Hepatology, Harvard Medical School, Boston, MA, USA
    Liver Int 28:150. 2008
  24. ncbi request reprint Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors
    Changqing Yang
    Program in Matrix Biology, Gastroenterology and Renal Divisions, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Gastroenterology 124:147-59. 2003
    ..The normal basement membrane-like matrix present within the space of Disse converts to a matrix rich in fibril-forming collagens during fibrosis...
  25. doi request reprint Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease
    Noah T Zinkin
    Liver Center, Department of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 14:470-7. 2008
    ....
  26. doi request reprint Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Gastroenterol Hepatol 6:242-7. 2008
    ..We hypothesized that a noninvasive test of liver fibrosis can accurately stage liver fibrosis. We prospectively evaluated the FIBROSpect II (FSII) biomarker panel versus pathology assessment and a quantitative measure of fibrosis...
  27. doi request reprint Diagnosis and quantitation of fibrosis
    Diarmuid S Manning
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, and Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 134:1670-81. 2008
    ..This article reviews the current role of liver biopsy in the assessment of hepatic fibrosis and discusses the role of the newer noninvasive methods including serum markers and radiologic tests...
  28. ncbi request reprint Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 21:2209-16. 2007
    ....
  29. ncbi request reprint Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
    John G McHutchison
    Duke University and Duke Clinical Research Institute, Durham, NC 27705, USA
    N Engl J Med 357:2227-36. 2007
    ..We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis...
  30. pmc Liver cirrhosis
    Detlef Schuppan
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 371:838-51. 2008
    ..This Seminar focuses on the diagnosis, complications, and management of cirrhosis, and new clinical and scientific developments...
  31. ncbi request reprint Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
    John G McHutchison
    ALT Alliance for Liver Therapy Group, Division of Gastroenterology and Hepatology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Hepatology 46:1341-9. 2007
    ..5-log(10) reduction. CPG 10101 was well tolerated, and adverse events were consistent with CPG 10101's mechanism of action...
  32. ncbi request reprint The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver
    Valerie Byrnes
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Gastroenterol 102:1654-9. 2007
    ..To evaluate the outcome of arterially enhancing nodules (AENs) measuring <20 mm detected on MRI in patients with cirrhosis...
  33. ncbi request reprint Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis
    Zachary D Goodman
    Armed Forces Institute of Pathology, Division of Hepatic Pathology, Veterans Administration Special Reference Laboratory for Pathology, Washington, DC, USA
    Hepatology 45:886-94. 2007
    ....
  34. ncbi request reprint Use of growth factors with antiviral therapy for chronic hepatitis C
    Michael P Curry
    Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
    Clin Liver Dis 9:439-51, vii. 2005
    ....
  35. ncbi request reprint Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index
    Thomas B Kelleher
    Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    J Hepatol 43:78-84. 2005
    ..To examine if serum fibrosis biomarkers could accurately identify the stage of liver disease amongst hepatitis C (HCV) and HIV co-infected patients...
  36. ncbi request reprint Management of hepatitis C virus in special populations: patient and treatment considerations
    Robert G Gish
    Liver Transplant Program and Division of Hepatology and Complex GI, California Pacific Medical Center, 2340 Clay Street 232, San Francisco, CA 94115, USA
    Clin Gastroenterol Hepatol 3:311-8. 2005
    ..Close monitoring and management of therapeutic side effects are required to assist these patients in adhering to therapy...
  37. ncbi request reprint The natural history of hepatitis C
    Nezam H Afdhal
    Medical Director, Liver Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Semin Liver Dis 24:3-8. 2004
    ..Progression of liver disease in 20 to 30% of patients can lead to compensated and eventually decompensated cirrhosis or hepatocellular carcinoma, or both. This article looks briefly at the epidemiology and natural history of hepatitis C...
  38. ncbi request reprint Antiviral therapy for treatment naïve patients with hepatitis C virus
    Sangik Oh
    Department of Medicine, Harvard Medical School, 25 Shattack Street, Boston, MA 02115, USA
    Gastroenterol Clin North Am 33:497-511, viii. 2004
    ..Recent data suggest that an SVR can be equated with a biochemical, virological,and histological response that is sustained for up to 5 years and is conceptually a cure of HCV in 90% of patients...
  39. ncbi request reprint Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis?
    Nezam H Afdhal
    Clin Chem 50:1299-300. 2004
  40. ncbi request reprint Evaluation of liver fibrosis: a concise review
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02125, USA
    Am J Gastroenterol 99:1160-74. 2004
    ..The limitations of utilization of these markers for both cross-sectional diagnosis of fibrosis and monitoring disease progression or regression are discussed...
  41. ncbi request reprint Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastroenterology 126:1302-11. 2004
    ..This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients...
  42. ncbi request reprint Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response
    Sanaa M Kamal
    Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Gastroenterology 130:632-8. 2006
    ..Pegylated interferon therapy has not been adequately evaluated in acute hepatitis C virus (HCV) infection. This randomized trial assessed the efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C...
  43. ncbi request reprint Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis
    Sanaa M Kamal
    Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Hepatology 43:771-9. 2006
    ..In conclusion, serial cytokine and fibrosis markers can accurately determine the rate at which fibrosis is progressing, identifying both those with rapid fibrosis and those with stable disease...
  44. ncbi request reprint Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C
    Gamal Esmat
    National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
    J Hepatol 46:620-7. 2007
    ..We evaluated whether surrogate serum biomarkers for liver injury are comparable to liver biopsy in Egyptian patients with hepatitis C virus (HCV) infection...
  45. ncbi request reprint Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
    Paul J Pockros
    Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 40:1450-8. 2004
    ..Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy...
  46. ncbi request reprint Race, insulin resistance and hepatic steatosis in chronic hepatitis C
    Hari S Conjeevaram
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:80-7. 2007
    ..32-0.91, P = 0.02). Insulin resistance but not steatosis was associated with a lower rate of sustained virological response when adjusted for known factors that predict response (relative risk 0.87, 95% CI 0.77-0.99, P = 0.028)...
  47. ncbi request reprint Iron, HCV, and liver cancer: hard metal setting the pace?
    Sebastian Mueller
    Gastroenterology 130:2229-34. 2006
  48. ncbi request reprint Duration of peginterferon therapy in acute hepatitis C: a randomized trial
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Hepatology 43:923-31. 2006
    ..Duration of treatment should be further optimized based on genotype and rapid virologic response at week 4...
  49. ncbi request reprint Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus
    Mark S Sulkowski
    Division of Infectious Diseases Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 19:585-92. 2005
    ....
  50. ncbi request reprint Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstones
    Helen H Wang
    Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, Massachusetts 02215, USA
    Gastroenterology 127:239-49. 2004
    ..It is hypothesized that estrogen enhances cholesterol cholelithogenesis by augmenting functions of hepatic estrogen receptors (ERs)...
  51. ncbi request reprint Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice
    Helen H Wang
    Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, MA, USA
    J Lipid Res 47:778-86. 2006
    ..These studies provide insights into therapeutic approaches to cholesterol gallstones in high-risk subjects, especially those exposed to high levels of estrogen...
  52. ncbi request reprint Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis
    Nezam H Afdhal
    J Hepatol 46:543-5. 2007
  53. ncbi request reprint The clinical significance of persistently normal ALT in chronic hepatitis B infection
    Michelle Lai
    Beth Israel Deaconess Medical Center, Division of Hepatology, Harvard Medical School, Boston, MA, USA
    J Hepatol 47:760-7. 2007
    ..The role of ALT levels as a predictor of liver injury has recently been questioned. The aim of the study was to determine whether normal ALT is associated with liver injury in a cohort of HBV patients undergoing liver biopsy...
  54. ncbi request reprint Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 46:324-9. 2007
    ..Adverse experiences were not different between IDN-6556 and placebo. There were no clinically meaningful changes in other laboratory parameters. In particular, mean HCV RNA levels did not show significant changes...
  55. ncbi request reprint The not so good effects of nitric oxide inhibition with methylene blue in cirrhosis and ascites
    Andres Cardenas
    Dig Dis Sci 52:939-40. 2007

Research Grants11

  1. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 2000
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..
  2. Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease
    Nezam Afdhal; Fiscal Year: 2007
    ..The goal of these studies is to determine whether there is a rationale for larger Phase 3 studies of silymarin in patients with chronic liver disease. ..
  3. CLINICAL CORE
    Nezam Afdhal; Fiscal Year: 2005
    ..abstract_text> ..
  4. Antiviral Therapy in African Americans with HCV
    Nezam Afdhal; Fiscal Year: 2005
    ..Specimens of liver tissue and serum will be collected for basic studies on viral resistance. These studies should help determine the best therapy for AA with HCV. ..
  5. Proteomics and Biomarkers for Hepatocellular Cancer
    Nezam Afdhal; Fiscal Year: 2004
    ..These studies may lead to identification of more specific and sensitive biomarkers for HCC in HCV which can then be validated further in prospective clinical trials. ..
  6. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 2002
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..
  7. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 2002
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..
  8. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 2001
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..
  9. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 2001
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..
  10. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 1999
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..